![Deshpande Wiesler Deshpande Wiesler](/sites/default/files/2024-08/Website_OhneLogo.jpg)
August 30, 2024
Boehringer Ingelheim announces appointments Board of Managing Directors
![Boehringer_Workplace_Lab_Research-01 Boehringer_Workplace_Lab_Research-01](/sites/default/files/2024-08/Boehringer_Workplace_Lab_Research-01_RGB_010.jpg)
August 27, 2024
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC
![Boehringer Ingelheim acquires Nerio Therapeutics in the lab](/sites/default/files/2024-07/Nerio.png)
July 29, 2024
Boehringer Ingelheim acquires Nerio Therapeutics
![CHMP-positive-opinion-SPEVIGO CHMP-positive-opinion-SPEVIGO](/sites/default/files/2024-07/CHMP-positive-opinion-SPEVIGO.jpg)
July 29, 2024
CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®
![Boehringer_Workplace_Lab_Research Boehringer_Workplace_Lab_Research](/sites/default/files/2024-07/Boehringer_Workplace_Lab_Research-01_CMYK_001%20resized.png)
July 18, 2024
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
![Ingelheim biomass plant inauguration cropped Ingelheim biomass plant inauguration cropped](/sites/default/files/2024-07/0O9A7814Bearb_cropped.jpg)
July 08, 2024
Boehringer Ingelheim produces its own green energy
![Boehringer Ingelheim advances SIRP immune-oncology program Pipettes with violet fluid](/sites/default/files/2024-07/PR_OSE2.jpg)
July 03, 2024
Boehringer Ingelheim advances SIRPα immuno-oncology program
![Phase 1 start for novel triple agonist obesity treatment Woman working in the lab on a laptop](/sites/default/files/2024-07/PR_Grupa.jpg)
July 01, 2024
Phase 1 start for novel triple agonist obesity treatment
![3-Lab-techs 3-Lab-techs](/sites/default/files/2024-06/3-Lab-techs-v2%20%281%29.png)
June 07, 2024
Survodutide shows breakthrough improvement in liver fibrosis
![Boehringer Ingelheim Economist Impact Boehringer Ingelheim Economist Impact](/sites/default/files/2024-05/Boehringer_Lifestyle_SocialLife_MeetingFriends-01_CMYK_018.png)
May 28, 2024
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
![Man in the lab Man working in the lab](/sites/default/files/2024-05/PR_OSE.jpg)
May 22, 2024
Partnership for first-in-class cancer and CRM treatments
![Sheep with bell are looking at camera Sheep with bell are looking at camera](/sites/default/files/2024-05/Bultavo%20press%20release.jpg)
May 13, 2024
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3)
![Hornbill Press Release Woman in the lab](/sites/default/files/2024-05/HornbillPR.jpg)
May 06, 2024
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
![Veterinarian treats dog, chicken is being held in barn Veterinarian treats dog, chicken is being held in barn](/sites/default/files/2024-04/Veterinarian%20treats%20dog%2C%20chicken%20is%20being%20held%20in%20barn.jpg)
April 25, 2024
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated
![boehringer_biopharmaceutical production_Biberach boehringer_biopharmaceutical production_Biberach](/sites/default/files/2024-04/boehringer_biopharmaceutical%20production_Biberach%20resized.jpg)
April 16, 2024
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
April 09, 2024
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
![EMPA EMPA](/sites/default/files/2024-04/EMPA%20image.png)
April 06, 2024
Results announced from EMPACT-MI phase III trial
![Boehringer Workplace Lab Research Boehringer Workplace Lab Research](/sites/default/files/2024-03/Boehringer_Workplace_Lab_Research-01_RGB_003%20%281%29.jpg)
March 19, 2024
SPEVIGO® approved for expanded indications in China and the US
![Boehringer_Lifestyle_SocialLife_MeetingFriends Two persons talking](/sites/default/files/2024-03/Boehringer_Lifestyle_SocialLife_MeetingFriends-01_RGB_008.jpg)
March 11, 2024
New partnership to develop schizophrenia treatments
![MASH MASH](/sites/default/files/2024-03/MASH_klein_1_0.png)
February 26, 2024
Survodutide Phase II trial shows groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
![Girl with horse in front of a camera](/sites/default/files/2024-02/Sleip_Partnership_website.png)
February 19, 2024
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
![doctor pointing on spine](/sites/default/files/2024-02/CBmed.jpg)
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
![Employee in learning environment](/sites/default/files/2024-01/Untitled%20design%20%281%29.png)
January 18, 2024
Global Top Employer 2024 certification reflects Boehringer Ingelheim’s impactful people development
![Koropi groundbreaking](/sites/default/files/2024-01/Koropi%20groundbreaking.jpg)
January 11, 2024
Boehringer expands production site in Greece for new medicine
![Man with cat](/sites/default/files/2024-01/SENVELGO%20wins%20Best%20New%20Product%20for%20Companion%20Animals%20award%E2%80%8B.png)
January 10, 2024
SENVELGO® wins Best New Product for Companion Animals award
![Scientists/doctors looking on a tablet](/sites/default/files/2024-01/ADVANCE.jpg)
January 09, 2024
New study paves the way for liver cirrhosis treatments
![Discussion of doctors and caregivers](/sites/default/files/2024-01/JPM_summary.jpg)
January 09, 2024
Kicking off 2024 with five new R&D partnerships
![Kyowa](/sites/default/files/2024-01/Malin_Kyowa_1.jpg)
January 05, 2024
Boehringer Ingelheim licenses a new compound as part of its commitment to people living with fibro-inflammatory diseases from Kyowa Kirin
![Partnership 3T Bio Partnership 3T Bio](/sites/default/files/2024-01/Malin.png)
January 04, 2024
Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies
![Scientists in the lab](/sites/default/files/2024-01/PR_Ribo.png)
January 03, 2024
Partnership for new liver disease treatments with Ribo
![Huebler_Schmelmer Huebler_Schmelmer](/sites/default/files/2023-12/Huebler_Schmelmer.jpg)
December 18, 2023
Boehringer Ingelheim announces appointments Board of Managing Directors
![Doctors in a discussion](/sites/default/files/2023-11/IBM%20PRess.jpg)
November 28, 2023
Partnership with IBM to accelerate new antibody therapies
![Diabetic cat with owner](/sites/default/files/2023-11/Diabetic%20cat%20with%20owner.png)
November 23, 2023
Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
![Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss](/sites/default/files/2023-11/BI_Workplace_Lab_Discussion-01_RGB_001%20%281%29.jpg)
November 22, 2023
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
![Asi+empa image.jpg](/sites/default/files/2023-11/Asi%2Bempa%20image.jpg)
November 03, 2023
Boehringer Ingelheim achieves major milestone in chronic kidney disease
![Life forward release 1](/sites/default/files/2023-10/MicrosoftTeams-image%20%2810%29.png)
October 30, 2023
Life forward - Boehringer Ingelheim unveils its evolved company brand
![Prix Galien 2023.jpeg](/sites/default/files/2023-10/Prix%20Galien%202023.jpeg)
October 30, 2023
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
![Phase III trials_image.png](/sites/default/files/2023-10/Phase%20III%20trials_image.png)
October 05, 2023
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
![Woman and Man in Computer room](/sites/default/files/2023-10/AdobeStock_160945102.jpeg)
October 02, 2023
Partnership with Precision Health Research, Singapore
![Eye in detail](/sites/default/files/2023-10/CRD_PR.jpg)
October 02, 2023
Phase 1 start of treatment for Geographic Atrophy patients
October 02, 2023
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
![KMP_tree_ClimateSeed_Ⓒ Permian Global 1440 x 810 plus Copyright 460kb.jpg](/sites/default/files/2023-09/KMP_tree_ClimateSeed_%E2%92%B8%20Permian%20Global%201440%20x%20810%20plus%20Copyright%20460kb.jpg)
September 14, 2023
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
![Man with cattle herd](/sites/default/files/2023-08/Credits%20%40GALVmed%20Karel%20Prinsloo.jpg)
September 05, 2023
New partnership working on solutions to combat African animal trypanosomiasis
![Obesity release.png](/sites/default/files/2023-08/Obesity%20release.png)
August 17, 2023
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
![Man with cat on sofa](/sites/default/files/2023-08/FDA%20Approval%20Senvelgo.jpg)
August 14, 2023
Boehringer Ingelheim receives FDA approval for SENVELGO®: the first oral liquid medication for diabetes in cats
![HY 2023 press release image](/sites/default/files/2023-07/HY%202023%20press%20release%20image%20resized.jpg)
August 01, 2023
First half of 2023: strong growth and expansion in key therapy areas
July 28, 2023
FRONTLINE® wins Brand of the Year Award for the third time in a row
![Kidney Diseases Kidney Diseases](/sites/default/files/2023-07/hands%20%26%20kidney%20image_1280x720_v01%5B37%5D.jpg)
July 25, 2023